Figure 4.

MPC deletion in CD8⁺ T cells blunts their antitumor potential

(A) Experimental scheme.

(B–D) Number of transferred cells in the blood at 10 days post-transfer (B) and their percentage of SLECs (C) and MPECs (D) (n = 11–12 mice/group; pooled data from 2 independent experiments).

(E) Percentage of T_CM cells among transferred cells in the spleen (n = 12 mice/group; pooled data from 2 independent experiments).

(F and G) Tumor growth (F) and weight (G) (n = 13–17 mice/group; pooled data from 3 independent experiments).

(H) T cell infiltration in tumors (n = 12 mice/group; pooled data from 2 independent experiments).

(I) Apoptotic tumor-infiltrating T cells (n = 12–13 mice/group; pooled data from 2 independent experiments).

(J) Expression level of Mpc1 and Mpc2 in cell clusters identified as progenitor exhausted (Tpex) and terminally exhausted (Tex) CD8⁺ T cells based on single-cell RNA-seq data (source: https://spica.unil.ch/), reported as normalized gene expression (ln norm. counts +1).

(K) Tumor-infiltrating T cells co-expressing PD1 and TIM3.

(L and M) Percentage of Tex (L) and Tpex (M) cells among the tumor-infiltrating transferred T cells (n = 11–12 mice/group; pooled data from 2 independent experiments).

(N and O) Percentage of splenic or tumor T cells expressing IFNγ, TNF, and IL-2 (N) or CD107a (O) (n = 16 mice/group; pooled data from 3 independent experiments, as shown in N, and n = 11 mice/group; pooled data from 2 independent experiments, as shown in O).

Data are represented as mean ± SEM. Statistics are based on unpaired, two-tailed Student’s t test (B–I and K–M), Wilcoxon test (J), or two-way ANOVA (N and O), ^∗p < 0.05, ^∗∗p < 0.01, ^∗∗∗p < 0.001, ^∗∗∗∗p < 0.0001, and ns (p > 0.05). See also Figure S4.